Management of clinical risks deriving from insertional mutagenesis

Table of contents

This document discusses the factors contributing to genotoxicity of vector integration, the strategies to reduce the risk associated to insertional mutagenesis and the assays to evaluate vector oncogenesis at the pre-clinical and clinical level.

Keywords: Gene therapy medicinal products, insertional mutagenesis, integration

How useful was this page?

Add your rating